Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Generic Drug Workload, Productivity Beating Budget Estimates

Executive Summary

ANDA submissions and approvals for FY 2017 likely to be higher than agency estimates, but FDA also predicts improved median approval time.


Related Content

Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
US FDA's Drug Shortage Effort Questioned By GAO
ANDA Withdrawals Increase Faster Than Approvals
GDUFA II: ANDAs, Not Facilities Will Govern Revenue
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
FDA Talent Hunt: Is Recruiting From Academia Better Than Industry?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts